X

Dr. Datasons Labs Ltd Stock Analysis

Small Cap
Evaluated by 479 users | BSE: 533412 | NSE: DRDATSONS |
Pharmaceuticals & Drugs
Aanjaneya Lifecare was born of a vision. Incorporated in 2006 it has evolved into a leading research based integrated pharmaceutical company with established research, manufacturing and marketing capabilities.  It is R&D focused, has a multi product portfolio with state of the art...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14
Return on Capital Employed 00033.22%20.74%23.83%23.93%13.23%7.8%2.87%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 00021.990.1162320480521421
Y-o-Y Gr. Rt.-NANANA311.9%79.4%98.1%49.9%8.5%-19.2%
Adjusted EPS (Rs.) 00011.5910.3225.5347.8329.2320.82-1.52
Y-o-Y Gr. Rt.-NANANA-11%147.4%87.4%-38.9%-28.8%-107.3%
Book Value per Share (Rs.) 00-21.921.4424.8886.16177.37251.89222.84128.85
Adjusted Net Profit 0002.35.114.836.240.628.9-4.8
Net Op. Cash Flow (Rs. Cr.) 000.1-2.3-21.90.5-45.8-45.839.7135
Debt to Cash Flow from Ops 004.14-5.32-1.72110.08-3.03-6.5113.873.67
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Dr. Datasons Labs Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales NA36.1%9.6%-19.2%
Adjusted EPS NA-168.2%-131.7%-107.3%
Book Value per Share 039-10.1-42.2
Share Price - - - -
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14
Return on Equity (%) 000108.761.5347.5139.3616.778.77-1.34
Operating Profit Margin (%) 00021.5512.0918.1122.1621.9720.3213.51
Net Profit Margin (%) 00010.65.679.1211.328.465.55-1.14
Debt to Equity 00-24.792.93.061.21.030.851.781.21
Working Capital Days 000140128146148202289499
Cash Conversion Cycle 000126124120137179187260
Entity Percentage Holding
Institutions 2.67%
Non-Institutions 97.33%
Pledged *94.4094.1990.4290.3290.2089.8787.7486.730.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Data is not available for this company.

Data is not available for this company

Aanjaneya Lifecare was born of a vision. Incorporated in 2006 it has evolved into a leading research based integrated pharmaceutical company with established research, manufacturing and marketing capabilities.  It is R&D focused, has a multi product portfolio with state of the art manufacturing facilities, and is set to become a marketing conglomerate across the globe. Aanjaneya has created a name for itself in the manufacture of bulk actives and finished dosage forms

Aanjaneya Lifecare was born of a vision. Incorporated in 2006 it has evolved into a leading research based integrated pharmaceutical company with established research, manufacturing and marketing capabilities.  It is R&D focused, has a multi product portfolio with state of the art manufacturing facilities, and is set to become a marketing conglomerate across the globe. Aanjaneya has created a name for itself in the manufacture of bulk actives and finished dosage forms its area of core competence. Driven by a top class team of managers and motivators this organization is counted as one of the most professional companies of India and a preferred place for top innovators and mangers to join the bandwagon of the globally significant Indian Pharma industry.

Its research team has proved itself to be a power house of innovation by filing many international patents for oncological therapeutics. The company is constantly working to broaden the pipeline of products and to make an impact in the international markets. The company reaches out to all the significant markets across South Asia and their distribution partners are highly dynamic, working to deliver the ideas and products to the market at great speed. Its contract manufacturing of these products provides great value to major marketing companies of the world working in India and the Europe. After ensuring a firm foundation of cost effective production capabilities and a clutch of loyal customers, the company is entering the high value specialty branded generic formulations segment, with a global marketing network. Last but not the least; the company is deeply committed to alleviate human suffering in the most ethical manner.

Patents

  • The company has received 5 product patents from Indian Patent office for Trans- dermal delivery system for Hormone Replacement Therapy.
  • The company has filed 3 world patents for improved and non infringing route of Synthesis of Anti Cancer Drugs Gemcitabine Hcl, Docetavel Anhydrous and Capecitabine.
  • The company has filed a World Patent for Extraction of Quinine hydrochloride directly from Quinine base using water as solvent.
  • The company has filed world patents for lozenges in therapeutic segments like Anti-smoking, Appetite enhancer, Irregular Bowel syndrome and erectile dysfunction.

Product Portfolio

  • Active pharmaceutical ingredients
  • Finished dosage forms
  • Herbal medicines
  • Inhalers
  • Lozenges
  • Animal health

Key Focus Areas

Research & Development

The company‘s R & D focus centers around the following:

  • Formulation & Development Department
  • Analytical Method Development Department
  • Active Pharmaceutical Ingredient Department

The company’s proposed objectives for R&D centre are:

  • To develop and transfer technology for Novel drug Delivery Systems (NDDS)
  • To chemically synthesize niche pharmaceutical products
  • To develop formulations for export markets; Generics for regulated markets and Innovative for non-regulated markets
  • To develop formulations to enable New Drug Application with the Drug Controller of India in the Ministry of Health
  • To develop and validate analytical procedures to support development of bulk drugs and formulations
  • To conduct bio-equivalence studies to assure high level of confidence and meet with time-lines
  • The proposed Aanjaneya R & D centre is located in Mahad, will be spread over an area of 10,000 sq. feet. The R & D facility is in process of being setup in and will be compliant to the Department of Scientific and Industrial Research, Govt. of India, requirements.

Technology Transfer Services

Consulting - Preparation of product and material specifications evaluation of existing production facilities to meet GMP definition of appropriate plant size and technologies

Project Appraisal - Financial and economic evaluations feasibility studies

Engineering - Design of plant layout, basic and detail engineering blue prints for civil engineering works

Plant Supply - Supply of plant equipment and supervision of erection and start up

Commissioning - Overall works supervision and supervision of erection and start up 

Training - Training schemes at Cipla's production facilities and on - the - job training courses 

Operational Management - Production planning and management 

Support - Raw materials management 

Know - How Transfer - Product know - how process know - how new developments. 

Quality Control - Development of analytical method, establishment of quality control guidelines according to GMP and quality control manuals.

Business Focus

The medium term strategy of the company is to continuously globalize the intellectual property assets and enhance value to customers.

In global markets, the company shall retain and enhance cost efficient quality leadership in anti malarial drugs. It is the endeavor of the company to achieve this by resolving complex chemistry challenges, improving process efficiencies, adopting global scale manufacturing and using cost effective market networks throughout South East Asia, Africa and Latin America.

The company’s competitive advantage is in capturing a large portfolio of approvals, backed up by a global standard R&D effort that offers several patented non-infringing processes and intellectual properties, and a cost efficient manufacturing environment complying with USFDA and EU authorities.

The company shall forge alliances with original research companies in the area of custom synthesis. The existing relationships and credibility will help Aanjaneya to acquire a significant part of bulk manufacturing of original research companies into its units.

The corporate plans are to ensure growth through organic and inorganic means, and by adopting strategic joint ventures and alliances. The objective is to maximize the revenues and reduce risks.

The long term growth strategies being put in to action include:

Develop a broad portfolio of DMFs through non-infringing processes and intellectual properties and become a significant player in the generics market, especially in the regulated markets

    Manage cost efficiently in a mega-manufacturing environment approved by USFDA/European regulatory authorities; and in the process, enhance its attractiveness to alliance partners

Emerge as a leading player in global high quality innovative specialty branded generic formulations and domestic brand segments

Leverage the strength in introducing innovative drugs in lozenges forms

Be an integrated player in fast developing herbal drugs segment by introducing range of formulations in Syrups, Lozenges, Tablets Capsules and gels for various therapeutic segments

Facilities 

Bulk Actives - Manufacturing facilities at Mahad MIDC

The company’s API complex in Mahad near Mumbai provides multi-therapeutic product offerings comprising high-end Alkaloids, Quinine Salts, and Veterinary APIs and Cytotoxic API's. Spanning 20,000 sq. mtrs, this facility is a world-class manufacturing complex which can handle complex synthesis and reactions with the highest levels of safety and productivity. The facility has an aggregate reactor capability of over 75 kl with reactors of varied metallurgy including cast alloy and several centrifuges, driers and production equipment. It is worth mentioning that the facility uses complex gases and a high technology hydro-genator system. The facility is also awarded the ISO 14001 (Environment Management System), ISO 9001:2008 and ISO 220000 certifications by BSI. The facilities are UK MHRA & EUGMP compliant.

The company proposes to implement Enterprise Resource Planning (ERP) at both plants and Head Office. Phase I will cover Finance, Supply Chain Management and Human Resource and Phase II will cover Manufacturing and Quality Control. This will manage all the hard data of its business including data on planning, purchase, inventory, manufacture, quality control, shipments, accounting and costing.

Finished Dosages Facility - Perungut Pune

Located in a site area of about 4 acres, the company’s Formulations Complex has facilities for manufacturing various types of dosage forms such as Liquid Syrups, oral tablets, lozenges and Gels in several product categories complying with international standards. It complies with WHO, cGMP, MHRA and TGA norms and has received ISO 9001, ISO 14001 and OHSAS 18001 (Occupational Health and Safety Management System) certifications; adequately reflecting Aanjaneya’s commitment towards quality and safety. Attainment of such standards have also opened the key to gaining footholds in regulated, lucrative markets like the US and EU for the company.

The overall facility and building design ensures the highest standards of aseptic manufacture, in compliance with the relevant Good Manufacturing Practices (GMP). The design of the building with dedicated HVAC systems and stringent controls on personnel and material movements are developed to avoid any cross-contamination of areas. Appropriate measures are taken to ensure that the product is contained within the building and particles do not escape to the external environment. The design incorporates, for this purpose, HEPA filters on air discharged to the external atmosphere and air locks where materials exit and enter, besides garment change protocols for personnel on entry and exit. This facility thus represents an advanced Liquid Filling line, comparable with the best in the world. The facility further reinforces Aanjaneya’s and India’s technical competencies in the global pharmaceutical industry.

Awards & Achievements

Excellence Award - The company’s Chairman Shri Kashi Vishwanathan received the Excellence Award from Former Hon. Dy. Prime Minister of Thailand Korn Dabaraasi at Indo - Thai Economic Cooperation Summit Held in Delhi in April 2009

Business Excellence Award - The company received the Business Excellence Award at World Summit of emerging India in July 2009

Quality Award - The company received the Quality Award from Europe Business Assembly in Vienna in December 2009

WHO GMP Certification - The company facilities have ISO 9001:2008, ISO 14001:2004 & ISO 22000 from BSI Systems and Pune facility has WHO GMP certification

Milestones

  • May 06, 2011 - Aanjaneya Lifecare enters into the capital market with an IPO of 50,00,000 equity shares
  • Jun 28, 2011 - The company receives Certificate of Suitability for two Bulk Drugs
  • Jun 29, 2011 - The company bags order worth Rs 60 crore from new clients
  • Jul 05, 2011 - The company features in the Top 100 of ‘India's Best Companies to Work for’ 2011
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback